Evidence map›Paper›PMID 40059620›Full record

ArticleBritish journal of haematology2025

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.

Meinolf Suttorp, Stephanie Sembill, Phyllis Lensker, Verena Hildebrand, Elke Schirmer, Axel Karow, Manuela Krumbholz, Manfred Rauh, Markus Metzler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meinolf SuttorpPediatric Hemato-Oncology, Medical Faculty, Technical University Dresden, Dresden, Germany.ORCID https://orcid.org/0000-0002-9522-8838
Stephanie SembillPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.
Phyllis LenskerPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.
Verena HildebrandPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.
Elke SchirmerPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.
Axel KarowPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.ORCID https://orcid.org/0000-0003-3963-7271
Manuela KrumbholzPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.ORCID https://orcid.org/0000-0002-4416-0394
Manfred RauhPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.
Markus MetzlerPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.

Funding

IZKF-ErlangenSächsische Landes- und Universitätsbibliothek (SLUB)Sonnenstrahl e.V. Dresden-Förderkreis für krebskranke Kinder und JugendlicheVerein Kaminkehrer helfen krebskranken Kindern
6 · The paper itself

Abstract

Imatinib (IMA) therapy for paediatric chronic myeloid leukemia (pCML) requires age-dependent dose adjustments. Assessment of therapeutic drug monitoring (TDM) under 'real-world' conditions was performed. Collection of blood and TDM-relevant data, calculation of individual dosage exposure, measurement of plasma C

Indexed as

Antineoplastic AgentsDrug MonitoringImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdolescentChildChild, PreschoolFemaleHumansInfantMaleAntineoplastic AgentsImatinib MesylateCMLimatinibpaediatric oncologypharmacokinetics

Identifiers

PMID40059620
PMCPMC12078881

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.